pancreatic cancer
Conditions
Interventions
S-1:80mg/day(BSA<
1.5/m2), day1-28. 1 cycle 6weeks, repeat 2 cycles before surgery
Sponsors
Hokkaido Pancreatic Cancer Study Group (HOPS)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Pathologically or cytologically proven diagnosis of pancreas cancer. 2) Definition of a Resectable pancreatic cancer is filled in NCCN guidelines 2012 pancreatic adenocarcinoma 3) Without distant metastasis 4) Patients of age =>20 5) Performance Status:0-1 (ECOG) 6) Adequate oral intake 7) Good main organ function 8) Written informed consent
Exclusion criteria
Exclusion criteria: 1) Treatment history of S-1 2) Treatment history of a pancreatic cancer 3) Regular use of frucitocin, fenitoin or warfarin 4) Patients who can' t receive neither iodic drug because of drug allergy 5) Lung fibrosis or intestinal pneumonia, and anamnesis or imaging findings 6) Massive pleural or abdominal effusion 7) Severe infection 8) Watery diarrhea 9) Uncontrolled diabetes 10) Simultaneous or metachronous (within 3 years) double cancers 11) Hemorrhagic peptic ulcer 12) Patients with severe disease 13) Patients requiring systemic steroids medication 14) Severe mental illness 15) Severe drug hypersensitivity 16)Pregnant females, possibly pregnant females, females wishing to become pregnant or Males that are currently attempting to produce a pregnancy 17)Patients seems inadequate for this study by investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Two year progression free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Two year overall survival, Resection rate, Pathological effect, Response rate, Adverse effect, Surgical complication | — |
Countries
Japan
Contacts
Public ContactToru Nakamura
Hokkaido University Gastroenterological Surgery II
Outcome results
None listed